Clinical Trial Update: Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20) [Phase 3]

View source ↗

Summary

Phase 3 trial update for epoetin alfa in advanced non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Lung Cancer
• Non-small Cell Lung Carcinoma

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Ontario Clinical Oncology Group (OCOG) | Conditions: Non-Small-Cell Lung Carcinoma, Lung Cancer | Phase 3 | Status: TERMINATED